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Human papillomavirus (HPV) is the most common sexually transmitted disease in 
the United States. It is also the primary cause of cervical cancer as well as other cancers. 
Fortunately, there are safe and effective vaccines to prevent HPV that are recommended 
for both men and women ages 9–26 years old. Unfortunately, vaccine uptake is 
considered low, leaving a need to increase HPV vaccine uptake across the U.S.  
This study examines trends in high-risk HPV positivity rates over the past 10 
years using large-scale laboratory test data, factors associated with vaccination in the 
published literature, and factors associated with intention to vaccinate in women age 18–
26 years old in Utah.  
Findings showed that HPV infection rates are likely falling, but at a rate that 
indicates less-than-optimal vaccination rates (consistent with CDC data). The trends in 
the published literature also indicate that intention to vaccinate is not increasing over 
time, and may actually be decreasing. Additionally, studies find physicians play a key 
role in influencing vaccination and are more likely to recommend to older woman. In 
Utah, physician’s recommendation, age, religious practices, relationship status, and 
education level were associated with vaccine intention.  
The results of this study can be used to inform future programs targeted at 
increasing HPV vaccination in Utah and perhaps in other low-vaccination states. For 
example, despite Advisory Committee on Immunization Practices (ACIP) 
recommendations for initiating HPV vaccination series in females aged 11 or 12 years, 
 iv 
and catch-up vaccination for females aged 13 through 26 years, we found that physicians 
are more likely to recommend vaccination at later ages. Additionally, our findings 
indicate that a strong physician recommendation significantly increases vaccination 
intention. These findings indicate the potential usefulness of a physician-focused 
intervention. 
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Human Papillomavirus (HPV) is the most common sexually transmitted infection 
in the United States, with peak prevalence among females 20–24 years of age  (Dunne et 
al., 2007; Hariri et al., 2011; Satterwhite et al., 2013). It is now understood that infection 
with high-risk human papillomavirus strains is necessary for the development of cervical 
cancer and precancerous lesions  (Bosch et al., 1995; Saslow et al., 2012). This implicates 
HPV in all cases of cervical cancer. Additionally, HPV plays a role in cancers of the head 
and neck  (Fakhry & Gillison, 2006; Gillison & Lowy, 2004).  
In 2006, the Food and Drug Administration (FDA) approved the first HPV 
vaccine. This was a quadrivalent vaccine (Gardasil®, Merck) offering protection against 
high-risk HPV (McLemore, 2006). Additionally, a second HPV vaccine, a bivalent 
vaccine (Cervarix®, GlaxoSmithKline) protecting against high-risk types 16 and 18, was 
approved in 2009  (Bouvard et al., 2009; Harper, 2009). Both vaccines have shown close 
to 100% efficacy and high observed effectiveness against HPV types 16 and 18, the cause 
of 70% of all cervical cancers  (Centers for Disease Control and Prevention (CDC), 
2012a; Markowitz et al., 2013). The Advisory Committee on Immunization Practices 
(ACIP) recommends vaccination for females 9 to 26 years old  (Markowitz et al., 2007).  
Since the time of initial vaccine approval, researchers have been modeling the 




(Barnabas et al., 2006). However, HPV vaccination rates vary by state and are considered 
low in both adults and adolescents  (CDC, 2013; Williams et al., 2014). These low 
vaccination rates would result in a more modest decline in HPV prevalence than would 
be seen with higher vaccination rates and would indicate a need for increased 
vaccination. 
Surveillance 
The first goal of this project is to design and evaluate a potential large-scale HPV 
surveillance system using national laboratory test data. Studies designed to monitor HPV 
infection, especially vaccine-preventable HPV types, and HPV-associated diseases can 
help determine the impact of HPV vaccines  (CDC, 2012b). Comprehensive surveillance 
data are not readily available for genital HPV infection, as HPV infection is currently not 
nationally notifiable  (CDC, 2012b; Weinstock, Berman, & Cates, 2004). Furthermore, 
HPV is considered difficult to estimate; that is, by criteria rating estimates of incidence 
and prevalence of STDs, rating of HPV is III (poor). Inconsistent, nonrepresentative 
prevalence data and estimates are based on rough extrapolations  (Weinstock et al., 
2004). Data from this project may then be useful to observe trends that can help 
determine the impact of HPV vaccines  (CDC, 2012b).  
Meta-Analysis 
The second goal of this study is to identify and amalgamate results of studies 
focusing on HPV vaccination, as many studies predicting HPV vaccination intention 
exist, but few studies exist to synthesize the many findings. While not the first meta-
analysis regarding the HPV vaccine  (Fisher, Trotter, Audrey, MacDonald-Wallis, & 




physicians’ intentions to prescribe the HPV vaccine. Additionally, the study examines 
individual and parental perceived safety and efficacy, physician recommendation, 
perceived severity, and/or perceived susceptibility to HPV, as predictors of intention to 
vaccinate young women. These synthesized findings will add to the current 
understanding of what drives HPV vaccination intention. 
Utah Survey 
The purpose of this third and final study is to assess the demographic and 
attitudinal factors that are associated with HPV initiation and completion among 18–26-
year-old women in Utah. HPV vaccination rates vary widely by country and by state 
within the U.S. Vaccination rates are lower in Utah than the national average, with 24.7% 
of Utah adolescents completing the series  (CDC, 2013). By contrast, more than 81% of 
eligible Utah children receive the tetanus, diphtheria, and acellular pertussis vaccine 
(Tdap)  (Williams et al., 2014).  
Our goal was to generate information that could be used to develop educational 
materials and intervention programs to increase HPV vaccination in women ages 18–26 
specifically in Utah. 
Study Setting, Data Sources, and Participants  
Study One 
The primary objective of study one is to estimate the positivity of high-risk HPV 
in the United States from 2004 to 2013 using retrospective data from HPV testing 
conducted at a National Reference Laboratory. These positivity rates and trends over time 
should reflect underlying prevalence rates in the population of women who undergo 




estimates of HPV vaccine impact.  
Data from patient test results archived in an electronic data warehouse were 
extracted for HPV results from January 1, 2004 to June 1, 2013 to produce 757,761 
female patient records with conclusive positive or negative results. Attached to each 
record were test results and demographic data, including age, sex, and client information. 
Using only the first observation for each patient per calendar year between 2004 and 
2013, a longitudinal dataset was created, consisting of 735,437 total high-risk HPV 
results from 590,036 unique patients at 692 unique client sites in 48 U.S. states.  
Study Two 
Study two will consist of a meta-analysis and systematic review of the literature 
regarding 1) physician intention to recommend HPV vaccine, 2) individual or parental 
intention to receive HPV vaccine, 3) uptake of HPV vaccine, and 4) factors associated 
with individual and parental intention to vaccinate.  
A systematic search of EMBASE, PsychInfo, Medline, PubMed, and Google 
Scholar identified 1,269 articles identified through database searches, of which 456 
abstracts were reviewed and 306 were relevant for vaccine intention or uptake. Of these, 
75 were included in the final analysis.  
Study Three 
This primary objective of study three is to study is to assess the demographic and 
attitudinal factors that are associated with HPV initiation and completion among 18–26-
year-old women in Utah.  
We recruited participants from the University of Utah Community Clinics through 




aged 18–26 years who had a University of Utah Community Clinic visit in the previous 
12 months. Potential participants were mailed a letter describing the project, a survey on 
attitudes toward the HPV vaccine, and a business reply envelope for easy return of the 
survey. 
Specific Aims 
Study One: Chapter 2 
Primary Objective: To design and evaluate a potential surveillance system for 
human papilloma virus using reference laboratory data for the purpose of evaluating 
vaccine impact. 
Study Two: Chapter 3 
Primary Objective: To perform a systematic review, meta-analysis, and meta-
regression of the existing literature on physician recommendation, intention, uptake, and 
factors driving intention to receive the HPV vaccine. 
Study Three: Chapter 4 
Primary Objective: To examine factors, as can be determined by a questionnaire, 
which are associated with stated vaccine uptake intentions to get vaccinated against HPV 
in women 18–26 years old in Utah. 
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SURVEILLANCE OF HUMAN PAPILLOMA VIRUS USING 
 
REFERENCE LABORATORY DATA FOR THE PURPOSE 
 




The purpose of this study is to present a method to estimate rate of change of 
high-risk HPV in the United States since 2004 in women using national reference 
laboratory data. Nationwide positivity rates of high-risk HPV for the United States before 
and since the introduction of an HPV vaccine in 2006 would provide insight into the 
uptake and impact of vaccination. These rate estimates would be representative of the 
sexually active population who undergo regular HPV screening – a target population for 
the HPV vaccine. 
We extracted data for high-risk HPV testing results from January 1, 2004 to June 
1, 2013 to produce 757,761 patient records of women between the ages of 14 and 59. 
Generalized linear models were created to assess differences in positivity between age 
categories and assess changes over time. Finite mixture models were used to investigate 
patterns within the distribution of time between sample collection and time of final result 
for all patients.  
Positivity rates for the high-risk HPV group was 27.2% for all age groups 




states and 692 sites were represented. While the positivity rates decreased for all age 
groups from 2004 to 2013, the 30 year and above age categories showed less of a 
downward trend following vaccine introduction, while the two age categories 20–24 and 
25–29 showed a significantly different downward trend between pre- and postvaccine 
time periods (-0.1% per year to -1.5% per year, and 0.4 % per year to -1.5% per year, 
respectively). All other age groups had rates of change that became less negative, 
indicating a slower rate of decline. 
Introduction 
Numerous studies have demonstrated a clear causal relationship between human 
papillomavirus (HPV) and cervical cancer, with HPV considered necessary but not 
sufficient to cause cervical cancer (Bosch et al., 1995; Doorbar et al., 2012; Lowy & 
Schiller, 2006; McIntosh, Sturpe, & Khanna, 2008; Song, Pitot, & Lambert, 1999; 
Walboomers et al., 1999). HPV also plays a causative role in vaginal, anal, head, and 
neck cancers (Fakhry & Gillison, 2006; Gillison & Lowy, 2004, 2010; Zandberg, 
Bhargava, Badin, & Cullen, 2013). HPV includes over 100 subtypes and is divided into 
high- and low-risk groups according to oncogenic risk. In 2006, a quadrivalent vaccine 
(Gardasil®, Merck) offering protection against high-risk types 16 and 18 and low-risk 
types 6 and 11, was approved by the Food and Drug Administration (FDA). Additionally, 
a bivalent vaccine (Cervarix®, GlaxoSmithKline) protecting against high-risk types 16 
and 18 was approved in 2009 (Bouvard et al., 2009). Both vaccines have shown close to 
100% efficacy against HPV types 16 and 18, the cause of 70% of all cervical cancers 
(Centers for Disease Control and Prevention (CDC), 2012a). In June 2006, the Advisory 




26 years old (Markowitz et al., 2007). It is hypothesized that with good vaccination 
coverage, the prevalence of HPV and HPV-associated cancers will decline (Barnabas et 
al., 2006). 
Although comprehensive surveillance for genital HPV positivity and prevalence 
data are considered difficult to estimate, several approximations exist (Satterwhite et al., 
2013). A 2007 report showed that the overall prevalence in the U.S. of any HPV infection 
prior to vaccine introduction (2003–2004) was approximately 27% (Dunne et al., 2007). 
A follow-up study published in 2013 showed the overall rate from 2007–2010 was 40% 
(Markowitz et al., 2013). Both of these studies estimate national level prevalence, but 
were conducted on limited sample sizes (less than 5000 per time period), and had 
conflicting rates, with the 2013 study reporting a prevalence during the years 2003–2006 
of 43% (Markowitz et al., 2013). Additional prevalence estimates exist, but these are 
often targeted at specific populations, lack sufficient sample size, are geographically 
isolated and often non-U.S. based (Banister et al., 2013; Dunne et al., 2013; Leinonen et 
al., 2013; Reiter et al., 2013; Škamperle, Kocjan, Maver, Seme, & Poljak, 2013; Walmer 
et al., 2013). Therefore, a need exists for surveillance with complete U.S. coverage to 
establish overall positivity and prevalence rates as well as trends in these rates (Centers 
for Disease Control and Prevention (CDC), 2012a; Wilson, Welch, & She, 2014). 
The goal of this study is to estimate the positivity of high-risk HPV in the United 
States from 2004 to 2013 using retrospective data from HPV testing conducted at a 
national reference laboratory (ARUP Laboratories, Salt Lake City, UT). These positivity 
rates and trends over time should reflect underlying prevalence rates in the population of 




other nationwide estimates of HPV vaccine impact. 
This study will illustrate that using such data can overcome the limitations of 
previous studies because the number of unique patients tested is large and account for a 
wide geographical spread. Additionally, since HPV testing is typically performed in 
conjunction with routine Papanicolaou (Pap) testing, and rates of routine testing are 
above 80% in U.S. women over 18 years of age, the data represent generalizable rates 
free from selection bias associated with testing typically performed to support clinical 
suspicion of disease (CDC, 2013). 
Methods 
Study Population and Analysis Datasets  
This study was approved by the University of Utah Institutional Review Board. 
Samples are submitted to and tested by ARUP Laboratories for high-risk HPV (genotypes 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). Data from patient test results 
archived in an electronic data warehouse were extracted for HPV results from January 1, 
2004 to June 1, 2013 to produce 757,761 female patient records with conclusive positive 
or negative results. Attached to each record were test results and demographic data 
including age, sex, and client information. Using only the first observation for each 
patient per calendar year between 2004 and 2013, a longitudinal dataset was created, 
consisting of 735,437 total high-risk HPV results from 590,036 unique patients at 692 
unique client sites in 48 U.S. states. 
HPV Testing 
Liquid-based endocervical samples were collected and submitted to ARUP 




Brushes (Qiagen, Hilden, Germany), ThinPrep® PreservCyt® media (Hologic, Inc., 
Marlborough, MA), and SurePath™ preservative (Becton-Dickinson, Franklin Lakes, 
NJ). Testing for HPV was performed according to manufacturer’s instructions by the 
Digene® hc2 HPV DNA Test, which utilized Hybrid Capture 2 technology. ThinPrep® 
PreservCyt® samples were prepared using the Digene® HC2 Sample Conversion Kit.  
Statistical Analysis 
Positivity rates were analyzed by age category and year (both individual year and 
year categories: 2004–2007, 2007–2013) and compared. Frequency tables and exact 
binomial confidence intervals were constructed to present positivity rates (with 95% 
confidence intervals [CI]) by age category and year. Generalized linear models (GLM) 
were created to assess differences in positivity between age categories and assess changes 
over time (McCullagh & Nelder, 1989). Two- and three-way interaction models were 
used to assess both how rates have changed in the pre- and postvaccine eras and also how 
age category affects this pre- and postvaccine era effect on rate, respectively. 
To account for potential bias associated with differences in ordering, several 
methods were employed. First, it was hypothesized that a positive bias might be 
associated with physicians who submit specimens for HPV testing based on abnormal 
cytology results (Shirts & Jackson, 2010). Therefore, finite mixture models were then 
used to investigate patterns within the distribution of time between sample collection and 
time of final result release for all patients (Figure 1) (Day, 1969; McLachlan & Peel, 
2000). Positivity rates between these different testing patterns were compared. 
Additionally, sensitivity analyses were performed using GLM to assess the effects of 




Nelder, 1989). Time between visits was calculated for patients with more than one visit 
as the average time between visits. Client size was calculated as number of tests ordered 
overall and for each year. Client consistency was an indicator variable representing 
whether or not a client had ordered tests both at the beginning and end of the study period 
(tests ordered in 2004 and 2013). These derived variables were compared for both their 
main effect on positivity rate and interaction effects with time on positivity rates.  
All calculations were performed using SAS software (v9.3, SAS Institute Inc., 
Cary, NC, USA). Results were considered statistically significant if p<0.05. 
Results 
Raw Positivity Rates: High-Risk HPV 
Positivity rates for high-risk HPV were separated and compared across time and 
by age groups (Table 1). Overall the positivity rate in women aged 14 to 59 years from 
2004 to 2013 (n=735,437) was 27.2% (95% confidence interval [CI], 27.1 to 27.3). When 
separated by time period, the positivity rates decreased over time, with the prevaccine 
introduction period (2004 to 2006) having an overall positivity rate of 35.3% (95% CI, 
35.1 to 35.5) and the final time period (2011 to 2013) having an overall positivity rate of 
19.7% (95% CI, 19.5 to 19.9). 
When separated by age group, each showed a significant decline in overall 
positivity over time. The largest absolute decrease was in the 30 to 39 year old age group, 
with a decrease from 27.2% (95% CI, 26.7 to 27.6), in the years 2004 to 2006, to 16.3% 
(95% CI, 16.1 to 16.6), in the years 2011 to 2013. The smallest absolute decrease was in 
the 25 to 29 year old age group, with a decrease from 44.0% (95% CI, 43.4 to 44.6), in 




1). Overall, current rates were highest in both the 14 to 19 year old and 20 to 24 year old 
age categories, with the positivity rate being 54.5% (95% CI, 52.9 to 56.2), and 54.7% 
(95% CI, 54.0 to 55.5), respectively in the years 2011 to 2013. 
Factors and Significance of Bias 
To establish if physician ordering practices influenced positivity, it needed to be 
determined if an indication for ordering HPV testing was present prior to sample 
submission. This was accomplished by analysis of the difference in collection time 
(reported by the client) and the result time (time at which results are reported from ARUP 
Laboratories). Finite mixture models were used and established two distinct populations 
of patient samples submitted; a population with a peak resulting time minus collection 
time at 3 days, and another at 8 days (Figure 1). A nadir (antimode) in the mixture model 
was observed at 5 days, which was then used as the cutoff between pattern 1 datasets (<5 
days) and pattern 2 datasets (>5 days). This is consistent with previous studies conducted 
at ARUP Laboratories and matches data that the majority of cytological results on Pap 
specimens are completed within 5 days (Clary et al., 2013; Shirts & Jackson, 2010). We 
also examined the subset of cases with both HPV test and Pap smear results to validate 
our assumption that HPV testing delayed beyond 5 days was likely the result of abnormal 
cytology results. This subset (n = 9,347) showed a bimodal peak, with normal cytology 
results associated with HPV test results on average 6 days later, whereas abnormal 
cytology results had HPV results reported on average 8 days later. Therefore, it is 
hypothesized that samples in the pattern 2 dataset were submitted with suspicion of HPV 
as a result of abnormal cytological findings and should be excluded from our estimates of 




compared to pattern 1 in all age groups across all years (Tables 1, 2). Additionally, 
sensitivity analyses performed using general linear models showed no statistically 
significant effect of time between visit, client size, and client ordering consistency on 
positivity rates. 
Trends: High-Risk HPV 
Following investigation of potential influences on the positivity rate and 
determining if they had significance or not, it was estimated that the positivity rates in 
pattern 1 should provide a useful indicator of underlying population prevalence of 
sexually active women getting regular gynecological screening. Overall positivity in this 
pattern 1 group of high-risk HPV for women aged 14 to 59 years from 2004 to 2013 was 
19.4% (95% CI, 19.3 to 19.6). Over time, the positivity rates decreased from 31.6% (95% 
CI, 31.2 to 32.0) during the years 2004 to 2006, to 13.2% (95% CI, 13.0 to 13.4) during 
the years 2011 to 2013. 
Women aged 14 to 19 years showed the largest absolute decrease in the pattern 1 
group in positivity from 55.5% (95% CI, 54.0 to 56.9) during the years 2004 to 2006, to 
43.0% (95% CI, 40.0 to 45.9) during the years 2011 to 2013. Women aged 50 to 59 
showed the largest percent decrease, dropping 49.7% in prevalence from 12.4% (95% CI, 
11.6 to 13.2) during the years 2004 to 2006, to 6.2% (95% CI, 5.9 to 6.6) during the years 
2011 to 2013. The smallest percent decrease was seen in women aged 20 to 24, with only 
an 18.0% reduction in positivity from 54.1% (95% CI, 53.1 to 55.1) during the years 
2004 to 2006, to 44.4% (95% CI, 43.0 to 45.8) during the years 2011 to 2013. 
Rates of change in high-risk HPV positivity per year were calculated and 




2013) in all age groups. Generalized linear models showed that age category had a 
significant effect on rates when these time periods were compared. In the pattern 1 group, 
all age categories showed positivity decreases in the postvaccine period; however, only 
women aged 20 to 24 and 25 to 29 showed negative differences (-1.4% per year and -
1.9% per year, respectively) when pre- and postvaccine period rates of change were 
compared. All other age categories had rates of change that were less negative, and closer 
to zero (Figure 2, Table 2). 
Discussion 
The goal of this study was to estimate the current positivity of and trends in high-
risk HPV in women in the United States from 2004 to 2013; specifically, in women who 
undergo regular gynecological screenings. These data indicate that the overall positivity 
of HPV is declining, especially in young women; however, the rate at which positivity is 
declining is slower than other studies indicate in certain age categories (Markowitz et al., 
2013). This may be a combination of insufficient vaccination coverage as well as these 
data being a mixture of vaccine-preventable and other high-risk types collectively. 
Mathematical models have predicted that the introduction of the vaccine should have a 
strong impact on HPV positivity rates in the types covered by the vaccine (Barnabas et 
al., 2006). While this data could not be separated entirely by type, a reduction of 18 to 
25% in positivity in all high-risk HPV was seen in women aged 14 to 29 when comparing 
rates prior to the vaccine introduction (2004 to 2006) to current rates (2011 to 2013). 
While most studies performed to determine HPV positivity or prevalence rely on 
survey-based methods, this study has several strengths that allow for the generalizability 




data were retrospective data from a large national reference laboratory, which created a 
large dataset of more than 700,000 high-risk HPV results that accurately reflected at-risk 
and vaccine-targeted population. Second, the data were filtered in several ways: only the 
first visit per calendar year of each patient was used to reduce redundancy that may occur 
as a result of repeat confirmatory testing, and potential ordering bias was reduced by 
separating results from patient samples believed to be submitted because of abnormal 
cytology results. To account for ordering bias, finite mixture modeling was used to 
determine where, if any, a separation may exist between the time the samples were 
collected and the time that results were entered (Day, 1969). The separation observed is 
likely the result of samples being immediately sent for HPV testing versus samples that 
had been screened for abnormal cytology before being sent for HPV testing (Shirts & 
Jackson, 2010). The cutoff between pattern 1 and 2 of 5 days can be further supported by 
a 2013 survey by the College of American Pathologists (CAP) that showed that 83.9% of 
Papanicolaou testing took less than 5 days to completion, with the majority taking 3 to 4 
days (Clary et al., 2013). Additionally, the positivity rates in testing pattern 2 were 
significantly higher than in testing pattern 1, suggesting physicians had an indication for 
ordering HPV testing, such as abnormal Pap smear results. Lastly, sensitivity analyses 
were performed to determine if differences in clients might influence the positivity rates. 
Since these data included many individual client sites, it was theorized that differences in 
client size might account for a bias in positivity: clients with fewer sample submissions 
may be targeting at-risk individuals with a higher likelihood of disease. Using 
generalized linear models, it was shown that there were no differences in positivity rates 




positivity rates truly are indicative of overall prevalence.  
Based on retrospective data from a national reference lab from 2004 to 2013, the 
overall positivity of high-risk HPV in all age groups was 27.2%. Looking at only pattern 
1, which was established as an estimate of unbiased prevalence, the rate drops to 19.4%. 
Our estimate of prevaccine high-risk HPV positivity in women 14 to 59 years old was 
31.6%, compared to the rates reported from other studies of 15 – 29% (Dunne et al., 
2007; Markowitz et al., 2013). For the current time period (2010–2013), the positivity 
rate decreases to 13.2% for all women aged 14 to 59. By age group, our positivity 
estimates are also higher, particularly in the 14-19 year old group (55–57%) when 
compared to CDC data (15–20%). This could be due to the fact that HPV testing is 
generally only performed for sexually active women; so positivity estimates in this study 
likely reflect the positivity rates in the sexually active population, which has been shown 
to be close to 50% in young adult females, similar to the present study (Dunne et al., 
2007; Markowitz et al., 2013). Furthermore, the method of specimen collection differed 
from other studies in that provider-collected cervical swabs were used as opposed to self-
collected cervicovaginal swabs. Provider collection could not feasibly be standardized in 
this study, but overall performance of HPV testing has been shown to be similar for both 
collection methods (Snijders et al., 2013). 
It is important to note that despite a decline in high-risk HPV positivity in all age 
categories, the rate of positivity change per year is not consistent. HPV vaccination is 
only recommended in women up to the age of 26; therefore, this group would likely have 
a faster decrease in positivity. It could further be postulated that, since the vaccinated 




prevalence per year would exist. This was observed, with the postvaccine introduction 
period rates of positivity change per year being consistent in the vaccine target group (age 
groups 14 to 19, 20 to 24, and 25 to 29) at a -1.5% and decreasing with each increase in 
age category to a low of -0.3% in the 50 to 59 year old group. The decreasing rates that 
were seen in the prevaccine introduction period are likely due to inconsistent testing 
practices among physicians and an increasingly heterogeneous population being 
screened; however, these rates still provide a baseline to compare postvaccine period 
rates. Crucially, the difference in the pre- and postvaccine era rates of positivity change 
were only more negative in the age groups that had overlap in vaccine and screening 
guidelines (20 to 24 and 25 to 29-year-old women). This suggests that the decreases in 
the rates of prevalence change per year seen in the younger population age categories 
could be due to increasing vaccination rates. 
For comparison, 618,261 Chlamydia tests were analyzed for females stratified by 
the same age categories as for HPV and covering years 2004–2013 (Figure 3). Across all 
age categories, there is no significant downward trend in positivity rates and, in fact, most 
age categories show an upward trend (especially since 2008). These results further 
support the hypothesis that downward trends observed in HPV are likely attributable to 
vaccine uptake.  
Several limitations to this study exist. Current guidelines recommend screening 
every 3 years in all sexually active women over 21 years of age; therefore, and as a result 
of the data being collected at a national reference lab, the population represented is likely 
a sexually active population with access to healthcare. Furthermore, cervical cancer 




introduction of co-testing HPV and Pap screening in women older than 30 years and 
recommendation against screening in women less than 21 years regardless of first sexual 
contact (Committee on Practice Bulletins—Gynecology, 2012; Saslow et al., 2012). 
Despite these changes, these data and several studies indicate that the guidelines are not 
being followed as testing is still frequently performed on an annual basis, in women 
under 21 years of age, and in women following hysterectomy (Kepka, Breen, King, 
Benard, & Saraiya, 2014; Roland et al., 2013; Shirts & Jackson, 2010). Another final 
limitation is that the Hybrid Capture 2 method does not differentiate genotypes and 
differentiation of specific high-risk vaccine preventable HPV strain was not possible 
(Castle et al., 2008; Sargent et al., 2010). 
We attempted to mitigate some of the potential biases by focusing on collection 
pattern 1 (results within 5 days of collection) and only including one visit within the 
calendar year, but future studies of this kind will certainly be needed to both validate and 
improve upon methodology. Additional studies that have access to multiple testing sites 
may be able to refine analyses by using characteristics of the different client sites: for 
example, differences in ordering volumes, within-center positivity rates, or information 
collected outside of the analytic framework, such as clinical indications for testing in 
their population. Our study demonstrates the potential for using HPV test data from large 
national reference laboratories to supplement the ongoing and planned efforts to monitor 
HPV vaccine impact in the US (Markowitz et al., 2010). 
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Table 1. Positivity of High-Risk HPV According to Age and Year Group 
in Pattern 1 Individuals from a National Reference Laboratory 
Age 
(years) 
2004–2013 2004–2006 2007–2010 2011–2013 
No. 
Positivity 
 (%) No. 
Positivity 
 (%) No. 
Positivity 
 (%) No. 
Positivity 
 (%) 
         
Overall 256,683 19.4 51,080 31.6 119,896 18.6 85,707 13.2 
14–19  10,979 50.6 4,692 55.5 5,224 47.8 1,063 43.0 
20–24 25,725 50.2 9,276 54.1 11,525 49.5 4,924 44.4 
25–29 24,363 36.8 7,545 41.2 11,219 36.8 5,599 30.8 
30–39 77,928 15.7 12,439 24.4 36,104 15.1 29,385 12.7 
40–49 67,841 9.5 10,824 14.7 31,955 9.0 25,062 8.0 
50–59 49,847 7.4 6,304 12.4 23,869 7.1 19,674 6.2 






Table 2. Average Rate of Change Is Positivity per Year 
Comparing Pre- and Postvaccine Periods 
Age, years 2004–2006 2007–2013 Difference 
    
14–19 -2.2 -1.5 0.7 
20–24 -0.1 -1.5 -1.4* 
25–29 0.4 -1.5 -1.9* 
30–39 -3.0 -0.8 2.2* 
40–49 -1.7 -0.4 1.3* 
50–59 -1.4 -0.3 1.1* 
    






Figure 1. Finite Mixture Modeling (FMM) of Time between 






Figure 2. High-Risk HPV Positivity in Pattern 1 Individuals by Year 




   
Figure 3. Comparison of Positivity Rates between High-Risk HPV (Pattern 
1 Individuals) and Chlamydia by Year and Age Category from 











FACTORS PREDICTING HUMAN PAPILLOMAVIRUS 
 
VACCINATION INTENTION AND UPTAKE: A META- 
 





Human papillomavirus (HPV) is the most common sexually transmitted infection 
worldwide. It is the primary cause of cervical cancer and is associated with cancers of the 
vulva, vagina, penis, and anus; additionally, HPV can cause oropharyngeal cancer. 
Despite the availability of effective vaccines, vaccination rates remain low. Many studies 
predicting vaccination intention exist, but few studies exist to synthesize the many 
findings. 
Methods 
Our database search strategy identified 1269 studies relating to physician 
recommendation, parental and individual intention, uptake, and factors relating to 
individual intention to receive the HPV vaccine. Three reviewers independently 
abstracted data and discrepancies were resolved by consensus between abstractors. All 
meta-analyses used random effects models with restricted maximum-likelihood (REML) 
to estimate between study variance. Subgroup analysis and meta-regression analysis were 





Of the 1,269 articles identified through database searches, 456 abstracts were 
reviewed and 306 were relevant for vaccine intention or uptake. Of these, 74 were 
included in the final analysis.  
For studies that considered physician recommendation, physicians were very 
likely to recommend or prescribe the HPV vaccine. However, this proportion varied 
significantly by the age category of the intended recipient, with physicians more likely to 
recommend or prescribe to older children and more likely still to recommend or prescribe 
for adults.  
We also summarized studies involving overall parental intention to vaccinate 
children, individual’s intention to vaccinate themselves, vaccine uptake, and odds ratios 
of factors predicting parental and individual intention to vaccinate and vaccine uptake.  
Conclusions 
Despite Advisory Committee on Immunization Practices (ACIP) 
recommendations for routine HPV vaccination of females aged 11 or 12 years, and catch-
up vaccination for females aged 13 through 26 years, we found that physicians are more 
likely to recommend vaccination at later ages.  
Additionally, findings on parental and individual intent and uptake and factors 
that drive them might better inform future interventions aimed at increasing HPV 
vaccination rates. 
Introduction 
Human papillomavirus (HPV) is the most common sexually transmitted infection 




currently considered the primary cause of cervical cancer (Bosch et al., 1995; 
Walboomers et al., 1999). Recognition of the link between HPV and cervical cancer led 
to the development of vaccines designed to prevent infection with certain high-risk types 
of HPV (Harper, 2009; Lowy, & Schiller, 2006; McLemore, 2006). The most prevalent 
HPV types (6, 11, 16, and 18) cause up to 70% of all cervical cancers (HPV16 and 18) 
and about 90% of genital warts (HPV6 and11) in young women ages 9–26 years (Dunne 
et al., 2013; Škamperle, Kocjan, Maver, Seme, & Poljak, 2013). In 2006, the Food and 
Drug Administration (FDA) approved Merck’s Gardasil® vaccine in girls and women 
ages 9–26 years (McLemore, 2006). This vaccine proved highly effective in preventing 
these four types of HPV. A second HPV vaccine, Cervarix®, developed by 
GlaxoSmithKline, targets the two most common HPV types associated with cervical 
cancer (HPV16 and 18; Harper, 2009). 
HPV vaccination rates vary by country and also by state within the U.S. Rates are 
considered low with only 34.8% of adolescent females in the U.S. having completed the 
vaccine series (3 doses) in 2011 (Centers for Disease Control and Prevention [CDC], 
2013; Williams et al., 2014). By contrast, more than 85–90% of eligible children in the 
U.S. are compliant with the Measles-Mumps-Rubella (MMR) series (Williams et al., 
2014). The CDC has named increasing HPV vaccination rates one of its top five priorities 
in 2014 (Greenberg, 2014). 
Hundreds of studies have been performed to investigate predictors of HPV 
vaccine intention and uptake in hopes of improving vaccination rates. However, as the 
number of studies increases, the need to organize and synthesize findings increases as 
well. To amalgamate results from the literature, we conducted a meta-analysis and 




not the first meta-analysis regarding the HPV vaccine (Fisher et al., 2013), the present 
meta-analysis adds to the literature by examining physicians’ intentions to prescribe the 
HPV vaccine. Additionally, the study examines individual and parental perceived safety 
and efficacy, physician recommendation, perceived severity, and/or perceived 
susceptibility to HPV, as predictors of intention to vaccinate young women. These 
synthesized findings will add to the current understanding of what drives HPV 
vaccination intention.  
Methods 
Data Collection 
We followed the MOOSE (Meta-analysis Of Observational Studies in 
Epidemiology) guidelines throughout the design, execution, and reporting of this study 
(Stroup et al., 2000). The key outcomes for this study were: a) reported proportion of 
physicians who intend to prescribe HPV vaccine, b) reported proportion of parents who 
intend to have their child receive the vaccine, c) reported proportion of individual women 
who intend to receive the vaccine themselves, and d) factors that predict intention to 
receive the HPV vaccination. Studies were included in the final analysis if they either 
included a reported count or proportion of physicians who intend to recommend the HPV 
vaccine, of parents who intend to get the HPV vaccine for their children, of individuals 
who either intend to receive the vaccine in the future or who have received the vaccine, 
or a reported odds ratio with 95% confidence interval for one or more of the key factors 
involved with intention to vaccinate, e.g., the increased odds of intention to vaccinate 
given a physician’s recommendation.  
A systematic search of EMBASE, PsychInfo, Medline, PubMed, and Google 











Proportions and odds ratios were abstracted by five reviewers (AW, AG, CCC, 
MJE, and AJ) and then double-checked independently by three reviewers (ARW, ATG, 
and CCC), with disagreements in abstracted values settled by consensus. For odds ratios, 
adjusted ORs were recorded when available; otherwise, crude ORs were recorded. Each 
paper was assigned a subjective quality score, ranging from 1–5, based on average of 
three reviewers’ scores (AW, AG, MJE). These scores were then converted to “high,” 
“moderate,” and “low” potential for bias from the average of the three reviewers. 
Agreement in quality assignment was greater than 80%. However, these scores were not 
used to exclude studies or used in analysis, as it has been proposed such use can actually 
introduce a source of bias (Greenland & O’Rourke, 2001). 
Assessing Heterogeneity 
Heterogeneity between studies was tested using Cochran's Q statistic and the 
proportion of heterogeneity due to variation between studies was quantified using the I2 
statistic (Higgins & Thompson, 2002; Schulze, Holling, & Böhning, 2003). The value of 
I2 describes the percentage of variability in point estimates that is due to heterogeneity 




equal to zero, so that I2 lay between 0% and 100%, where a value of 0% indicated little or 
no observed heterogeneity, and larger values showed increasing heterogeneity (Higgins 
& Thompson, 2003). Besides quantifying the amount of heterogeneity present, we tried 
to explore the potential causes of the heterogeneity. We did this visually by using forest 
plots, and analytically using subset analysis and meta-regression to investigate whether 
particular covariates explained a substantial proportion of the heterogeneity of effects 
between studies (Thompson & Higgins, 2002). For proportions and odds ratios, we 
considered the following as possible covariates: year study data were collected, age of 
potential vaccine recipient, and country or continent of study origin. Covariates were 
considered both in terms of statistical significance and reduction in heterogeneity, i.e., 
reduction in I2 value. 
Statistical Amalgamation  
Binary estimates for proportion intending to vaccinate were calculated by taking 
the exact binomial proportion and standard error of the number of those declaring 
intention or uptake over total number of participants within the study. Calculation of an 
overall proportion of physicians intending to recommend HPV vaccine was performed 
using random effects meta-analysis of single proportions using logit transformation 
(Viechtbauer, 2010). Calculation of overall odds ratios for individual predictors was 
performed using meta-analysis, applying generalized linear (mixed-effects) models (Van 
Houwelingen, Zwinderman, & Stijnen, 1993; Viechtbauer, 2010). For both proportions 
and odds ratios, restricted maximum-likelihood estimators were used to estimate the 
between-study variance τ (Hariri et al., 2011; Viechtbauer, 2010).  
Amalgamation of main effects, tests of study heterogeneity, and subgroup 




(2013). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ (Viechtbauer, 
2010).  
Results 
Of the 1,269 articles identified through database searches, 456 abstracts were 
reviewed and 306 were relevant for vaccine intention or uptake. Of these, 74 studies met 
all inclusion criteria for our analysis. A flow chart for this selection schema is presented 
in Figure 4 and descriptions of included studies are given in Table 3.   
Physician’s Intention to Prescribe HPV Vaccine 
There were six studies on physician endorsement or recommendation of the HPV 
vaccine (Barnack, Reddy, & Swain, 2010; Duval et al., 2007; Feemster, Winters, Fiks, 
Kinsman, & Kahn, 2008; Henninger, 2009; Kahn et al., 2005; Kahn et al., 2008). The 
proportion of physicians who intended to prescribe the HPV vaccination ranged from 
66% to 97%. However, there was a high degree of heterogeneity (overall I2 = 96.4%) 
between studies (Figure 5). A significant amount of heterogeneity could be attributed to 
the age of intended recipient, with physicians more likely to recommend vaccination to 
older girls. The proportion of physicians likely to vaccinate were 73% (95% CI: 68%-
78%), 89% (95% CI: 76%–95%), and 95% (95% CI: 84%–98%) for recipients aged less 
than 14 years, 14–17 years, and greater than 17 years, respectively (p=0.0014). Still, 
heterogeneity was high within these age categories and specific estimates of pooled 




Parents’ Intention to Have Daughters Vaccinated 
Overall, 26 studies reported parents’ intention to vaccinate their daughters: 15 
studies conducted in the U.S. (Allen et al, 2010; Askelson et al., 2010; Barnack et al, 
2010; Bernat, Harpin, Eisenberg, Bearinger, & Resnick, 2009; Constantine & Jerman, 
2007; Dempsey, 2009; Fazekas, Brewer, & Smith, 2008; Gerend, Weibley, & Bland, 
2009; Gottlieb et al., 2009; Guerry et al., 2011; Litton, Desmond, Gilliland, Huh, & 
Franklin, 2011; Perkins, Pierre-Joseph, Marquez, Iloka, & Clark, 2010; Podolsky, 
Cremer, Atrio, Hochman, & Arslan, 2009; Rahman, Elam, Balat, & Berenson, 2013; 
Rosenthal et al, 2008) and 11 studies conducted outside the U.S. (Brabin, Roberts, 
Farzaneh, & Kitchener, 2006; Dinh et al., 2007; Hofman et al., 2014; Korfage, Essink-
Bot, Daamen, Mols, & van Ballegooijen, 2008; Lenselink et al., 2008; Marlow, Waller, 
& Wardle, 2007; Ogilvie et al., 2007; Sam et al., 2009; Tozzi et al., 2009; Woodhall et 
al., 2007). Of the 26 studies reporting parental intention to vaccinate, 9,973 out of 13,831 
parents (72.1%) reported intention to vaccinate their daughter against HPV. This 
proportion was higher in studies outside the U.S. (84%) compared to studies conducted 
inside the U.S. (61%) (Figure 6). Of the 21 studies reporting vaccine uptake in women, 
256,246 out of 498,266 (51.4%) had received (adult women) or reported that their 
daughter had received (young women) one or more HPV shot. There was high 
heterogeneity between studies (I2=98.4%) (Figure 6). There were significant differences 
between intention proportions from studies conducted within the U.S. versus studies 
conducted outside the U.S. (p=0.0165), with studies in the U.S. reporting lower intentions 
(Table 4). There was also a downward trend in parental intention by study year; however, 
trend rates, adjusted for age of intended recipient and whether or not study was conducted 




intended recipient and whether study was conducted within or outside the U.S., 
heterogeneity was substantially reduced from 98.4% to 16.3%.  
Individual Women’s Intention to Receive Vaccine for Themselves 
There were 25 studies that focused on individuals’ intention to receive the HPV 
vaccine for themselves (Allen et al., 2009; Blumenthal et al., 2009; Casey, Crosby, 
Vanderpool, Dignan, & Bates, 2013; Chan, Yan, Lo, Cheung, & Hung Chung, 2009; 
Christian, Christian, & Hopenhayn, 2009; Cui, Baldwin, Wiley, & Fielding, 2010; Di 
Giuseppe, Abbate, Liguori, Albano, & Angelillo, 2008; Forster, Marlow, Wardle, 
Stephenson, & Waller, 2010; Gerend, Lee, & Shepherd, 2007; Gerend & Magloire, 2008; 
Hsu et al., 2009; Jones & Cook, 2008; Juraskova, Bari, O'Brien, & mcCaffery, 2011; 
Kahn, Rosenthal, Hamann, & Bernstein, 2003; Katz et al., 2009; Kwan et al., 2009; 
Kwan, Tam, Lee, Chan, & Ngan, 2011; Li et al., 2009; Moreira et al., 2006; Mortensen, 
2010; Watts et al., 2009; Wong, 2008; Wong & Sam, 2010; Woodhall et al., 2007; Young 
et al., 2010). Although overall intention appears high, there was a high degree of 
heterogeneity between studies (I2 = 98.8%) and intention estimates ranged broadly from 
26% to 89%, depending on the study (Figure 8). However, much of the heterogeneity 
could be attributed to country of study and year data were collected. After adjusting for 
age of intended recipient and whether study was conducted within or outside the U.S., 
heterogeneity was substantially reduced from 98.8% to 14.3% (Table 5). Additionally, 
there was a significant downward trend in individual intention to vaccinate by study year 
(-4%/year; p-value = 0.0112) after adjusting for age of intended recipient and whether or 






Overall, 21 studies reported HPV vaccine uptake (1+ doses) (Brewer et al., 2011; 
Caskey, Lindau, & Alexander, 2009; Fisher et al., 2013; Gottlieb et al., 2009; Guerry et 
al., 2011; Jain et al., 2009; Kahn et al., 2008; Kang & Moneyham, 2010; Laz, Rahman, & 
Berenson, 2013; Li et al., 2013; Mathur, Mathur, & Reichling, 2010; Mortensen, 2010; 
Perkins et al., 2010; Rahman et al., 2013; Reiter, Brewer, Gottlieb, McRee, & Smith, 
2009; Spencer Nee Pilkington, Brabin, Verma, & Roberts, 2013; Steens et al., 2013; 
Stöcker, Dehnert, Schuster, Wichmann, & Deleré, 2013; Taylor et al., 2014; Tsui et al., 
2013). Heterogeneity was extremely high between studies (I2 = 99.8%). Meta-regression 
indicates a significant association between age (in years) of vaccine recipient and uptake 
(Table 6). There was also a negative association with year study was performed, 
indicating a downward trend. Additionally, studies in the U.S. showed lower uptake than 
studies outside the U.S., while adjusting for year and age of recipient. However, neither 
of these results were statistically significant. 
Vaccination Intention by Belief in HPV 
Vaccine Safety and Efficacy 
There were five studies relating belief in the safety and efficacy of the HPV 
vaccine to intention to vaccinate. Four of these studies involved individuals’ intention (Di 
Giuseppe et al., 2008; Hsu et al., 2009; Juntasopeepun, Suwan, Phianmongkhol, & 
Srisomboon, 2012; Krawczyk et al., 2012), and one study involved parental intention to 
vaccinate their children by belief in safety and efficacy (Baldwin, Bruce, & Tiro, 2013). 
There was high heterogeneity between the four studies on pooled intention (I2=91.48%) 
and therefore pooled estimates may not be appropriate. The one study involving parental 




1.97-4.4]). All studies indicate people who believe in safety and efficacy of vaccine are 
more likely to intend to vaccinate or get their children vaccinated, with odds ratios 
ranging from 1.11 to 2.95 (Figure 10).  
Vaccination Intention by Physician Recommendation 
There were seven studies investigating physician recommendation as a predictor 
of vaccine intention. Five of these studies involved individual intention (Di Giuseppe et 
al., 2008; Hsu et al., 2009; Juntasopeepun et al., 2012; Krawczyk et al., 2012; Young et 
al., 2010), and two studies investigated how physician recommendation affected parental 
intention to vaccinate their child (Gottlieb et al., 2009; Hanley et al., 2012). The five 
studies on individual intention had low heterogeneity (I2 = 0.00%) with an amalgamated 
(adjusted) odds ratio for these four studies of 1.32 [95% CI: 1.23-1.41] (Figure 11). The 
two studies on physician recommendation and parental intention had identical odds 
ratios, 12.60, and the pooled confidence interval was 8.07-19.67.  
Vaccination Intention by Belief in Susceptibility to HPV 
A total of nine studies examined the relationship between belief in susceptibility 
to HPV and intention to receive the vaccine. Of these nine studies, five involved 
individual intention (Di Giuseppe et al., 2008; Hsu et al., 2009; Juntasopeepun et al., 
2012; Kahn et al., 2008; Krawczyk et al., 2012) and four involved parental intention 
(Baldwin et al., 2013; Hanley et al., 2012; Hofman et al., 2014; Marlow et al., 2007). 
There was moderate heterogeneity between studies involving individual intention 
(I2=52.21%) and the pooled estimated odds ratio was 1.20 [95% CI: 1.10-1.32] (Figures 
12 and 13). However, there was high heterogeneity between studies on parental intention 




studies indicated a positive association between belief in susceptibility and vaccine 
intention and uptake, both in individuals and parents (8 of 9 ORs >1).  
Vaccination Intention by Belief in Severity of HPV 
There were seven studies relating belief in the severity of HPV (including 
progression to cervical cancer) to intention to receive HPV vaccine. Five of these studied 
involved individual intention (Di Giuseppe et al., 2008; Hsu et al., 2009; Juntasopeepun 
et al., 2012; Kahn et al., 2008; Krawczyk et al., 2012) and two involved parental intention 
to vaccinate their children (Baldwin et al, 2013; Hofman et al., 2014). There was high 
heterogeneity between the studies of individual intention (I2=86.44%), with odds ratios 
ranging from 0.90 to 1.39 (Figure 14). The two studies on parental intention had 
contradictory findings, with one study reporting an odds ratio less than 1 (0.79 [95% CI: 
0.51-1.22]) and the other with an odds ratio greater than 1 (1.22 [95% CI: 1.03-1.46]). 
Discussion  
Our findings show that physicians are very likely to recommend or prescribe the 
HPV vaccine overall, but are less likely to recommend the vaccine for younger recipients, 
specifically those aged less than 14 years. This runs contrary to the Advisory Committee 
on Immunization Practices (ACIP) recommendations for routine HPV vaccination of 
females aged 11 or 12 years or catch-up vaccination in women 13–26 years of age.  
Physician recommendation was a strong predictor of vaccination intention. 
Recognizing the low heterogeneity among studies of individual intention (I2 = 0.00%), 
and that all studies used in our meta-analysis showed a positive association (ORs from 
1.26 to 12.60), we are confident that there is a positive association and physician 




Perceived severity of HPV infection was not a strong predictor of individual or 
parental intention to vaccinate. However, there were significant associations between 
belief in efficacy of the vaccine and belief in susceptibility to HPV and individual 
intention to vaccinate. This has strong implications for vaccination messaging, suggesting 
that focusing on severity of HPV and its progression to cervical cancer is not likely to be 
a useful measure to increase vaccine intention as focusing on efficacy and susceptibility 
(e.g., high prevalence of HPV), as well as focusing on getting doctors to adopt stronger 
positive messaging.  
Although not a primary outcome, our results show that rates are lower in the U.S. 
versus other countries for both intention and uptake when adjusting for the year study 
data were collected and age of potential recipient (Tables 4 and 6). Future studies could 
compare messaging and vaccination programs that prove to be successful either outside 
the U.S. or using positive deviance analysis to identify successful U.S. programs to 
bolster rates within the U.S. (Cassidy & Schlenk, 2012). 
Results in Relation to a Meta-Analysis 
of Vaccine Acceptability among Men 
In 2013, Newman, Logie, Doukas, and Asakura published a meta-analysis of 29 
cross-sectional studies of vaccine acceptability among men. They calculated mean 
acceptability across studies (on a 100 point scale), and performed a meta-analysis on 
studies reporting correlates of vaccine acceptability. Among the 22 investigations 
reporting HPV vaccine acceptability, the mean acceptability ranged from 8.2 to 94.0 (on 
a scale of 0-100) with overall mean acceptability of 56.6 (SD 21.3; Newman et al.). 
These acceptability mean results are lower than values we found for both parental 




Among their study’s key influential correlates of HPV vaccine acceptability 
among men were perceived HPV vaccine effectiveness (6 studies, r= 0.19, p<0.001, 
I2=58.36) and healthcare provider recommendation (5 studies, r= 0.42, p<0.01, I2=92.13; 
Newman et al., 2013). Although using different measures, these results are consistent 
with our findings regarding perceived efficacy and physician recommendation as being 
strongly associated with vaccine intention in women.  
Strengths and Limitations 
Strengths of this study were a broad and inclusive search of the literature, 
independent data abstraction by three researchers with disagreements in abstracted values 
settled by consensus, and attention to predictors of uptake and intention to vaccinate. 
Further, we used subgroup analysis and meta-regression to investigate sources of 
heterogeneity. 
There are several potential limitations. Results for uptake are limited to young 
women. Substantial heterogeneity between studies limited our ability to amalgamate their 
results. In addition, adjusted odds ratios were adjusted for a variety of variables. 
Subgroup analysis and meta-regression did reduce heterogeneity, but for some 
proportions, such as percent uptake and percent intention, ranges are preferable to overall 
estimates, as high heterogeneity may invalidate combined estimates.  
A potential source of variation in odds ratios included in this study is that almost 
all papers used different sets of adjustment variables (Table 3), or no adjustment 
variables, indicating widely varying rationales in how researchers considered their 
statistical modeling. This is an issue of confounding bias in the reported odds ratios, in 
contrast to the issue addressed by meta-regression, which adjusts for an 




potential method to address this is to consider a causal diagram, i.e., a directed acyclic 
graph (DAG), for each exposure of interest (Shrier & Platt, 2008). From these diagrams, 
minimally sufficient sets of adjustment variables could be identified, which would avoid 
confounding bias in the estimate of the odds ratio (Greenland, Robins, & Pearl, 1999). 
Furthermore, there may be several alternative sufficient sets of study variables that could 
be used to address bias, or, in some cases, the sufficient adjustment set is null and the 
crude odds ratio is suitable (Oakes & Kaufman, 2006). However, currently, protocols to 
address sufficiency of adjustment within the context of a meta-analysis do not exist, and 
it would be useful if they could be developed.  
Another potential source of variation between studies of intention to vaccinate 
could be the different scales used to measure predictors of intention. For example, for 
individual belief in susceptibility and intention to vaccinate, one study used a 5-point 
Likert scale (Hsu et al., 2009) and another used a 10-point Likert scale (Di Giuseppe et 
al., 2008). However, results of meta-regression indicate no significant effect of scale on 
the odds ratios. Nevertheless, future studies may develop techniques to adjust for 
different scales of odds ratios and put amalgamated estimate on common scale where 
appropriate.  
Conclusions 
Physician recommendation is a strong predictor of vaccination intention, and 
physicians are more likely to recommend vaccine to older versus younger female 
patients. Although it does appear that parental intention to vaccinate is decreasing over 
time, it is too soon to draw a strong conclusion based on these studies alone. However, 
these findings do support the statements of the CDC (2012) that progress toward 




their efforts by talking to parents about the importance of HPV vaccine just as they do 
other vaccines. As such, CDC officials urge healthcare providers to increase the 
consistency and strength of their recommendation of the HPV vaccine, especially when 
patients are 11 or 12 years old.  
At the present time, 8 years post-HPV vaccine-approval, campaigns to increase 
HPV vaccination uptake might better focus on physician scripting and adherence to 
guidelines, than on potential recipient’s attitudes toward the vaccine, especially focusing 
on trust in safety and effectiveness over susceptibility and severity of HPV as a motivator 







Table 3. Summaries of Included Studies 
Year 
published Authors Country 
Study time 
period Study location (geographical) Study population 
Risk of 
bias 
       
2009 Blumenthal, J. et al. USA  (unclear) Before 
2009 
New York 162 female aged 13 to 18 years High 
2008 Wong, L. Malaysia 2008? Malaysia 40 young unmarried women 
aged 13 to 27 years 
High 
2007 Gerend, M. et al. USA July to 
November 2005 
North Florida 58 primarily low-income 
minority women aged 18 to 50 
High 
2009 Chan, S. et al. China January to June 
2006 
Hong Kong 250 female aged 12 to 19 years High 
2010 Kang, H. et al. South 
Korea 
April to June 
2008 
South Korea 1359 female aged 18 to 32 years Moderate 
2003 Kahn, J. et al. USA 2002? Cincinnati 52 female aged 18 to 30 years Moderate 
2009 Katz, M. et al. USA Summer of 2007 Ohio Appalachia counties 114 women aged 18 to 26 years Moderate 
2009 Podolsky, R. et al. USA 2009 New York City and El 
Salvador 
308 mothers of children aged 8 
to 18 
Moderate 
2007 Duval, B. et al. Canada April to 
December 2006 
Nova Scotia (NS), Quebec 
(PQ), Ontario (ON) and 
British Columbia (BC) 
1282 physicians Moderate 
2008 Feemster, K et al. USA December 2006 
to February 2007 
Pennsylvania 105 pediatric clinicians Moderate 
2009 Henninger, J New 
Zealand 
May 2008 Christchurch, New Zealand 155 general practitioners and 
practice nurses 
Moderate 
2009 Reiter, P. et al. USA July to October 
2007 
North Carolina 889 parents of girls aged 10 to 
18 years 
Moderate 
2013 Stocker, P. et al Germany Septemberto 
December 2010 
Berlin 442 students aged 14 to 19 years Moderate 
2014 Taylor, V. et al. USA Nine month 
period during 
2012 and 2013 
Seattle 86 Cambodian mother with a 
daughter aged 9 to 17 years 
Moderate 
2013 Tsui, J. et al. USA January to 
November 2009 
Los Angeles County 468 mothers of girls aged 9 to 18 
years 
Moderate 
2013 Casey, B. et al. USA March 2008 to 
September 2009 
Southeastern Kentucky 495 women aged 18 to 26 years Moderate 






Table 3. Continued 
Year 
published Authors Country Study time period Study location (geographical) Study population 
Risk of 
bias 
       2008 Gerend, M. et al. USA February to 
March of 2007 
Florida State University and 
Florida A&M University 
124 students aged 18 to 26 years Moderate 
2011 Juraskova, I. et al. Australia June to August 
2007 
University of Sydney 159 female aged 17 to 27 years Moderate 
2009 Li, J. et al. China September 2005 
to June 2007 
geographically and socio-
culturally diverse areas of 
China. 
6024 women aged 14 to 59 years Moderate 
2010 Perkins, R. et al. USA June 2007 to 
February 2008 
Massachusetts 76 parents of girls aged 11 to 18 
years 
Moderate 
2013 Rahman, M. et al. USA September 2011 
to February 2013 
Galveston, Beaumont and 
Angleton, Texas 
456 mothers with a child aged 9 to 
17 years 
Moderate 
2005 Kahn, J. et al. USA Two-month 
period in 2004 
USA 513 pediatricians and family 
physicians 
Moderate 
2010 Young, A. et al. Philippines June to July 2009 Central Visayan region, 
Philippines 
435 women aged 18 to 52 years Moderate 
2010 Mortensen, G. Denmark January 2009 Denmark 749 women aged 16 to 26 years Moderate 
2010 Reiter, P. et al. USA 2008 North Carolina 617 parents of adolescent females 
aged 10 to 17 years 
Moderate 
2006 Moreira, E et al. Brazil May to July 2002 Salvador City, Brazil 204 female participants aged 16 to 
23 years 
Moderate 
2010 Cui, Y. et al. USA April to 
December 2007 
Los Angeles County, CA. 2295 women aged 18 to 55 years Moderate 
2011 Kwan, T. et al. China July to November 
2008 
Hong Kong 943 adolescents girls Moderate 
2009 Watts, L. et al. USA August 2007 to 
April 2008 
Massachusetts 227 Latina and non-Latina women 
aged 18 to 55 years 
Moderate 
2010 Wong, L.et al. Malaysia April to 
December 2007 
Kuala Lumpur, Malaysia 650 Malaysian female students 
attending a public university 
Moderate 
2009 Marlow, L. et al. UK November 2006 
to February 2007 
England, Scotland, and Wales 332 women with a daughter aged 
16 years or younger 
Moderate 
2010 Askelson, N. et al. USA 2008 Rural, Midwest state 217 mothers who had daughters 
aged 9 to 15 years 
Moderate 
2013 Li, S. et al. Hong Kong November 2011 
to January 2012. 
Hong Kong 1820 female aged 18 to 27 years Moderate 
2009 Mathur, M. et al. USA August 2007 to 
February 2008 
California 156 high school girls in 9th 






Table 3. Continued 
Year 
published Authors Country Study time period Study location (geographical) Study population 
Risk of 
bias 
              
       
2009 Christian, W. et al. USA Fall 2005 Kentucky 2169 women aged 18 years or 
older 
Moderate 
2007 Lenselink, C. et al. Netherlands 2006 Nijmegen 356 parents of children aged 10 to 
12 years 
Moderate 
2007 Dinh, T. et al. Vietnam First 3 weeks of 
June 2005 
Da Nang, Vietnam 181 women who were the primary 
caregiver of a girl aged 10 to 18 
years 
Moderate 
2010 Barnack, J. et al. USA Fall 2006 Nationwide 100 parents and 100 physicians Moderate 
2008 Fazekas, K. et al. USA April to May 2006 Person County, North Carolina 146 women Moderate 
2008 Di Giuseppe, G. et 
al. 
Italy March to May 
2007 
Campania, Italy 1341 women aged 14 to 24 years Low 
2007 Marlow, L. et al. UK February to June 
2006 
Guildford, Norfolk, Lambeth, 
Nottingham 
680 mothers of girls aged 8 to 14 
years 
Low 
2011 Brewer, N. et al. USA Summer 2007 to 
Fall 2008 
North Carolina 650 parents of girls aged 10 to 18 
years 
Low 
2013 Fisher, H. et al. England September 2008 
to November 
2010 
South West of England 14282 young women born between 
September 1995 and August 1998 
Low 
2009 Jain, N. et al. USA May to August 
2007 
Nationwide 1102 were women aged 18 to 49 
years 
Low 
2013 Spencer, A. et al England 2011 North West of England 117343 girls aged 12 to 16 years Low 
2013 Steens, A. et al. Netherlands 2011 Netherlands 337368 girls aged 13 to 16 years Low 
2012 Juntasopeepun, P.et 
al. 
Thailand May to August 
2011 
Northern region of Thailand 747 women aged 18 to 24 years Low 
2009 Hsu, Y. et al. Taiwan October 2007 to 
April 2008 
5 universities in southern 
Taiwan 
845 female undergraduates aged 
17 to 36 years 
Low 
2008 Kahn, J. et al. USA October 2006 to 
May 2007 
Cincinnati, Ohio, USA 409 female participants aged 13 to 
26 years 
Low 
2012 Krawczyk, A. et al. Canada between 2009 to 
2010 
McGill University, Quebec, 
Canada 
447 female undergraduates aged 
18 to 43 years 
Low 






Table 3. Continued 
Year 
published Authors Country 
Study time 
period Study location (geographical) Study population 
Risk of 
bias 
       
       
2009 Allen, J et al. USA February to 
March 2007 
Massachusetts 1401 women aged 18 to 22 years Low 
2008 Jones, M. et al. USA 4/1/2006 A northeastern university 202 women aged 18 to 32 years Low 
2009 Kwan, T. et al. China February to 
November 2007 
Hong Kong 1450 ethnic Chinese women 
aged 18 or above 
Low 
2009 Gerand, M. et al USA January to June 
of 2008 
Southeastern 82 parents with at least one child 
less than 18 years of age 
Low 
2008 Korfage, I. et al. Netherlands 2007 Netherlands 1367 wonen Low 
2011 Litton, A. et al. USA December 2008 
to April 2009 
Alabama 403 female caregivers of girls 
aged 10 to14 years. 
Low 
2009 Sam, I. et al. Malaysia May 2007 Kuala Lumpur 362 Malaysian mothers with 
childeren aged 18 years or 
younger 
Low 
2007 Constantine, N. et 
al. 
USA Spring and 
Summer 2006 
California 522 parents with daughters aged 
18 years or younger 
Low 
2009 Dempsey, A. et al. USA January to March 
2007 
Michigan 52 mothers of girls aged 11 to 17 
years 
Low 
2013 Laz,T. et al. USA 2010 Nationwide 1892 female aged 18 to 26 years Low 
2012 Baldwin, A. et al. USA December 2008 
to May 2010 
Greater Dallas, Texas 256 mothers or female guardians 
of girls aged 8 to 22 years 
Low 
2009 Gottlieb, S et al. USA July to October 
2007 
North Carolina 889 parents or guardians of girls 
aged 10 to 18 years 
Low 
2009 Tozzi 2009 Italy October to 
December 2007 
Italy 807 mothers with a daughter 
aged 10 to 12 years 
Low 
2009 Bernat, D. et al. USA September 2006 
to March 2007 
Minnesota 1504 parents of children aged 5 
to 18 years 
Low 
2006 Brabin, L. et al. UK March to April 
2005 
Manchester 317 parents of children aged 11 
to 12 years 
Low 
2012 Hanley, S. et al. Japan July to 
September 2010 








Table 3. Continued 
Year 
published Authors Country 
Study time 
period Study location (geographical) Study population 
Risk of 
bias 
       
2013 Hofman, R. et al. Netherlands June 2009 to 
November 2011 
Netherlands 793 parents who had not 
yet made the decision to have 
their daughter vaccinated 
against HPV, but had to decide 
within 
3–15 months when their 
daughters became 12 
years of age. 
Low 
2008 Rosenthal, S. et al. USA April 2007 to 
January 2008 
USA 153 mothers with daughters aged 
11 to 17 years 
Low 
2010 Allen, J et al. USA September 2007 
to January 2008 
Nationwide 451 Parents of girls aged 9 to 17 
years 
Low 
2009 Caskey. R. et al. USA November 2007 Nationwide 1011 female aged 13 to 26 years Low 
2007 Ogilvie, G. et al. Canada June 2006 to 
March 2007 
Canada 2083 parents of children aged 8 
to 18 years 
Low 
2011 Guerry, S. et al USA October 2007 to 
June 2008 
California 503 parents/guardians of girls 
aged 11 to 18 years 
Low 






Table 4. Regression Coefficients for Meta-Regression 
of Parental Intention to Vaccinate Daughter 
Variable Coefficient SE p 95% CI 
     
Year data collected -0.0389 0.0206 0.0586  (-0.0792, 0.0014) 
Age of intended recipient 
(years)  
-0.0261 0.0178 0.1419  (-0.0610, 0.0087) 
Study in U.S. (vs. not) -0.1564 0.0652 0.0165*  (-0.2843, -
0.0286) 
     
Note. All effects adjusted for each other. I2 (residual heterogeneity / unaccounted 
variability): 16.27%. Test for Residual Heterogeneity: 





Table 5. Regression Coefficients for Meta-Regression of Vaccine Intention (Individual) 
Variable Coefficient SE p 95% CI 
     
Year data collected -0.0437 0.0172 0.0112*  (-0.0775, -0.010) 
Age of intended recipient 
(years)  0.0034 0.0035 0.3341  (-0.004, 0.0103) 
Study in U.S. (vs. not) -0.1090 0.0616 0.0771  (-0.2298, 0.0119) 
     
Note. I2 (residual heterogeneity / unaccounted variability): 14.29%. Test for 




Table 6. Regression Coefficients for Meta-Regression of Female Vaccine Uptake 
Variable Coefficient SE p 95% CI 
     
Year data collected -0.0146 0.0311 0.6384  (-0.0756, 0.0463) 
Age of intended recipient 
(years)  -0.0298 0.0178 0.0087** 
 (-0.052, -
0.0075) 
Study in U.S. (vs. not) -0.1656 0.1093 0.1296  (-0.3798, 0.0486) 
     
Note. 1+ doses; all effects adjusted for each other. I2 (residual heterogeneity  
/ unaccounted variability): 81.78%. Test for Residual Heterogeneity: 
QE (df = 19) = 99.6664, p-val < .0001. 












Figure 5. Meta-Analysis Forest Plot of Proportion of Physicians Who Intend to 
Prescribe/Recommend HPV Vaccine (by Intended Age of Recipient).  
Test for Subgroup Differences between Age Categories (Random 
Effects Model) Q (df = 2) = 13.2, p = 0.0014 
 







Figure 6. Meta-Analysis Forest Plot of Proportion of Parents (with 95% CI and  
Random-Effects Weighting Per Study) Who Intend to Have Their Daughter 








Figure 7. Meta-Regression Plot of Proportion of Parents Who Intend to Have 
Their Daughter Receive the HPV Vaccine by Year of Study 
and Whether Study Was Conducted in U.S.



























U.S. Study Study outside U.S.
I2=38.77%
Test for Residual Heterogeneity:
QE(df = 24) = 38.4814, p-val = 0.0309
p-val trend = 0.0086





Figure 8. Meta-Analysis Forest Plot of Proportion of Individuals Who Intend 








Figure 9. Meta-Regression Plot of Proportion of Individuals Who Intend to Receive 
the HPV Vaccine by Year and by Whether Study Was Conducted in U.S.
  
  



























size of symbol proportional to study weight U.S. Study Study outside U.S.
I2 = 14.29%
Test for Residual Heterogeneity:





Figure 10. Meta-Analysis Forest Plot of Odds Ratios for an Individual’s 
Belief in Vaccine Safety and Efficacy as a Factor for Vaccination 
Intention and Uptake for that Individual
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Figure 11. Meta-Analysis Forest Plot of Odds Ratios for Physician Recommendation 
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* Adjusted Odds Ratio
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Test for Heterogeneity:





Figure 12. Meta-Analysis Forest Plot of Odds Ratios for an Individual’s 
Belief in Susceptibility to HPV as a Factor for Vaccination 
Intention and Uptake for that Individual 
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Figure 13. Meta-Analysis Forest Plot of Odds Ratios for an Individual’s Belief in 
Susceptibility to HPV as a Factor for Parental Vaccination Intention and Uptake
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Figure 14. Meta-Analysis Forest Plot of Odds Ratios for an Individual’s Belief in 
Severity of HPV Infection (Including Progression to Cervical Cancer) as a  
Factor for Vaccination Intention and Uptake for that Individual
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FACTORS RELATED TO HPV VACCINE UPTAKE AND 
 
3-DOSE COMPLETION AMONG WOMEN IN A LOW- 
 





The objective of this study is to assess the demographic and attitudinal factors 
associated with HPV vaccine initiation and completion among 18–26-year-old women in 
Utah.  
Method 
Between January 2013 and December 2013, we surveyed 325 women from the 
University of Utah Community Clinics about their HPV vaccine related beliefs and 
behaviors. Odds ratios (ORs) were estimated from logistic regression models to identify 
variables related to HPV vaccine initiation and series completion.  
Results 
Of the 325 participants, 204 (62.8%) had initiated the vaccine and 159 (48.9%) 
had completed the 3-dose series. The variables associated with HPV vaccine initiation 
were lower age (OR = 1.18 per year); being unmarried (OR = 3.62); not practicing 
organized religion (OR = 2.40); knowing how HPV spreads (OR = 6.29); knowing the 




preventive vaccination (OR = 2.45 per scale unit); strength of doctor recommendation 
(OR = 1.86 per scale unit); and whether a doctor's recommendation was influential (OR = 
1.70 per scale unit). These variables were also significantly associated with HPV vaccine 
completion.  
Discussion 
Our findings may be used to develop interventions to improve HPV vaccination 
rates among young women in Utah. 
Introduction  
The American Cancer Society estimates that in 2014, there will be over 12,000 
new cases of invasive cervical cancer diagnosed in the United States and over 4,000 
women will die from this disease (“What Are the . . . ,” 2014). Human papillomavirus 
(HPV), the most common sexually transmitted infection (Centers for Disease Control and 
Prevention [CDC], 2014a; Satterwhite et al., 2014), has been shown to be necessary to 
cause cervical cancer (Bhatia et al., 2013; Lowy & Schiller, 2006; Walboomers et al., 
1999). Recognition of this link led to the development of vaccines protecting against 
infection with certain high-risk types of HPV. There are currently two HPV vaccines 
available: Merck’s Gardasil® vaccine (CDC, 2013b), proved highly effective in 
preventing the highest prevalence HPV types 16 and 18 (which cause up to 70% of all 
cervical cancers), as well as HPV types 6 and 11 (which cause about 90% of genital 
warts) [Bhatia et al., 2013; Bosch et al., 1995; CDC, 2012; Hariri et al., 2014); and 
GlaxoSmithKline’s Cervarix® vaccine (CDC, 2013a), targeting the two most common 
oncogenic HPV types (16 and 18) (Bhatia et al., 2013; Hariri et al., 1995). 




Immunization Practices (ACIP) recommended a 3-dose HPV vaccination series as a 
routine vaccine for girls age 11–12 years old (Markowitz et al., 2007). Vaccine 
administration is optimal at this age because adolescents have the best immunoresponse 
to the vaccine and likely have not yet been exposed to the virus (Markowitz et al., 2007). 
However, the ACIP also recommended the HPV vaccination series as a catch-up vaccine 
for young women age 13–26 years old (Markowitz et al., 2007). It is hypothesized that 
with good vaccination coverage, the prevalence of HPV and HPV-associated cancers will 
decline (Barnabas et al., 2006; Lowy & Schiller, 2006; Markowitz et al., 2007; 
Markowitz et al., 2013). 
Despite this opportunity for cervical cancer prevention, HPV vaccination rates are 
low in the United States. In 2013, just 57.3% of adolescents age 13–17 years old had 
received 1 dose of the vaccine, and only 37.6% had completed the 3-dose series (Elam-
Evans et al., 2014). Coverage is especially poor in Utah, with just 44.3% of Utah 
adolescents initiating the vaccine, and 20.5% completing the 3-dose series (Elam-Evans 
et al., 2014). Most recent data indicate that uptake is the worst among young women: 
only 34.5% of women age 19–26 years old report receiving at least 1 dose of the HPV 
vaccine (Williams et al., 2014). State-specific data for this age group are unavailable. In 
spite of this low HPV vaccine coverage, recommendations from physicians remain 
suboptimal for all age groups (Vadaparampil et al., 2014). 
While the choice whether or not to vaccinate adolescent usually falls to their 
parents, young women who are eligible to receive the vaccine are able to make the 
decision for themselves. These women are responsible for their own health, so their 




different from those of the parents of young adolescents. There have been many studies 
on women’s beliefs and behaviors related to the HPV vaccine, but few studies have 
specifically focused on a state with low HPV vaccine initiation and completion rates 
(Brewer & Fazekas, 2007; Gold, Naleway, & Riedlinger, 2013; Kennedy et al., 2011; 
Kepka et al., 2014; Kharbanda et al., 2013; Rosenthal et al., 2011; Verdenius et al., 2013; 
Weiss, Rosenthall, & Zimet, 2011).  
The purpose of this study is to assess the demographic and attitudinal factors 
associated with HPV initiation and completion among 18- to 26-year-old women in Utah. 
Our goal is to generate information to develop intervention programs to increase HPV 
vaccination in this age group in Utah.  
Methods 
This study was approved by the University of Utah Institutional Review Board. 
Survey Creation  
Previous studies have used Health Belief Model (HBM) constructs (Donadiki et 
al., 2014; Reiter et al., 2009) and/or Social Cognitive Model (SCM) factors (Chan et al., 
2009) to identify predictors of HPV vaccination intention. The HBM considers potential 
motivating factors such as perceived severity (an individual's assessment of the 
seriousness of the condition), perceived susceptibility (an individual's assessment of their 
risk of getting the condition), expected benefit (an individual's assessment of the positive 
rewards of adopting the behavior), self-efficacy, and perceived barriers (Bandura, 1997). 
Each question included in our survey corresponded to a conceptual variable representing 
one facet in either HBM or SCM (Bandura, 1997, 2001). Survey items were also 




and shared with permission (Greenland, Pearl, & Robins, 1999; Rosenthal et al., 2011).  
Our study questionnaire included six sections:  
1. Attitudes about health,  
2. Attitudes about vaccines,  
3. Demographic information and history/family history of cancer,  
4. Attitudes about reproductive health,  
5. Attitudes about the HPV vaccine, and  
6. Future (intended) HPV vaccine use. 
Data Collection 
We recruited participants from the University of Utah Community Clinics through 
the University of Utah Primary Care Research Network. An initial data query of potential 
participants was performed to identify young women age 18–26 years old who had a 
University of Utah Community Clinic visit in the 12 months preceding the query. Two 
groups of 1,000 were created. In the first group, we included 336 women who had at least 
one documented dose of the HPV vaccine and 664 unvaccinated women. In the second 
group, we included 233 who had initiated the vaccine and 776 unvaccinated women. 
Potential participants were sorted by zip code and only those within the catchment areas 
for the University of Utah Community Clinics were included in the sample. Potential 
participants were mailed a letter briefly describing the project and given the opportunity 
to opt out. Remaining participants were mailed a letter describing the project in greater 
detail, a paper version of the survey, and a business reply envelope to return the survey. 
Introduction letters with study opt-out information went out in two waves of 




excluding nine opt-outs, we had a response rate of 84 of 991 surveys (8.5%). The target 
response rate for analysis was between 300–325 completed surveys. In order to improve 
return rates, the implementation protocol was revised, following the Tailored Design 
Method proposed by Dillman, Smyth, and Christian (2009). Modifications to the survey 
wave, according to the Dillman method, included:  
• 1,000 opt-out letters and cover letters were printed in high-resolution color 
and hand-signed, 
• Surveys now included a 5$ bill thank you with return envelope, and  
• Address verification services were used. 
These revisions bolstered returns from 8.5% to over 27.1% (244 surveys 
completed of 901 delivered). All surveys were mailed between January and December 
2013.  
Data Analysis 
Fisher’s Exact Tests and Logistic Regression were used to determine differences 
in demographics, initiation, and completion rates between the two waves of survey 
responses to assess appropriateness of pooling results. Summary statistics for participant 
characteristics were calculated by vaccination status. Principal component factor analysis 
with promax rotation was used for the attitude questions to derive useful attitude factor 
variables. Correlation between items in factor variables was assessed using Cronbach’s 
alpha (Table 7).  
A Directed Acyclic Graph (DAG) (Figure 15) was created to help identify and 
adjust for potential confounders and minimize bias assessing individual predictors of 




Platt, 2008). An online tool, DAGitty (http://www.dagitty.net), was used to produce 
potential DAGs and derive minimally sufficient adjustment sets for predictor variables 
(Textor, Hardt, & Knuppel, 2011). Univariate and multivariate logistic regression models 
were used to calculate odds ratios (ORs) to identify variables related to vaccine initiation 
and series completion.  
Factor and Principal Component Analysis was performed using R (R Core Team, 
2013). Descriptive statistics and univariate and multivariate logistic regression was 
performed using SAS software, Version 9.4 of the SAS System Copyright © 2013 SAS 
Institute Inc., Cary, NC, USA. Results were considered statistically significant if p<0.05. 
Results 
A total of 84 of 993 surveys (8.5%) from the first wave and 244 of 901 surveys 
(27.1%) from the second wave were returned for a total of 328 of 1,983 returned (16.5%). 
Three participants were excluded: 2 for having an age out of range and 1 for 
incompleteness of the questionnaire. The remaining 325 were included in the final 
analysis. There were no statistically significant differences in age (p=0.1286), race 
(p=0.9336), marital status (p=0.3268), education (p=0.3135), initiation of the vaccine 
series (p=0.6935), or completion of vaccine series (p=0.3756) between the participants in 
the two survey waves, so the two waves were pooled for the analysis.  
Of these 325 participants, 204 (62.8%) had initiated the vaccine series and 159 
(48.9%) had completed the 3-dose series. Of the 45 who had initiated, but not completed 
the vaccine series, 31 (70.5%) said they intended to complete the series and 13 (29.6%) 
said they did not (1 missing). The mean age for those who initiated the vaccine was 22.4 




years), and for those who did not receive any vaccine doses was 23.3 years (s.d. 2.3 
years). Participant characteristics are presented in Table 8 and participants’ HPV vaccine-
related knowledge and attitudes are presented in Table 9. 
The factor analysis produced a total of seven attitude factors with good interitem 
correlation. As explained in Table 7, the factors produced were: 
1. Attitudes toward vaccines [Cronbach’s alpha: 0.902],  
2. Regular gynecological care [Cronbach’s alpha: 0.855],  
3. Comfort with sexual health (care) [Cronbach’s alpha: 0.753],  
4. External locus of health control 1: (medical professionals drive health) 
[Cronbach’s alpha: 0.722],  
5. Internal locus of health control [Cronbach’s alpha: 0.735],  
6. External locus of health control 2: (health matter of luck) [Cronbach’s alpha: 
0.644], and  
7. Comfort with shots [Cronbach’s alpha: 0.729]. 
Table 10 shows the significant univariate predictors of vaccine initiation were lower age 
vs. older age: OR = 1.18 per lower year [95% CI: 1.07 – 1.30]; marital status (being 
unmarried vs. married): OR = 3.62 [95% CI: 2.18– 5.99]; not practicing vs. practicing 
organized religion: OR = 2.4 [95% CI: 1.49 – 4.0]; knowledge of HPV transmission: OR 
= 6.29 [95% CI: 3.46 - 11.44]; known connection between HPV and cervical cancer: OR 
= 3.90 [95% CI: 2.21 - 6.89]; known importance of vaccine (to help prevent cervical 
cancer): OR = 2.45 [95% CI: 1.79 - 3.36]; strength of doctor recommendation: OR = 1.86 
per Likert scale unit [95% CI: 1.27 - 2.70]; and a binary indicator of whether a 




variables were all also significant predictors of completion of the 3-dose series (see Table 
10). Minimal sufficient adjustment sets were derived from application of the DAG (see 
Figure 15) to produce subsets of variables adequate to control for potential confounding. 
These subsets were used to produce adjusted estimates (see Table 10). 
The main reasons for not intending to initiate or complete the vaccine were 
waiting for more information/vaccine too new (n=38), married or monogamous 
relationship (n=36), cost of vaccine or unsure if insurance covers vaccine (n=23), concern 
of side effects (n=18), not sexually active (n=14), and vaccine inconvenience (n=7) (see 
Figure 16). 
Discussion 
The HPV vaccine has been available in the United States for 8 years, yet only one 
third of adolescents have been fully immunized with all 3 recommended doses, and only 
one third of older eligible women (age 18–26 years old) have received just 1 dose of the 
3-dose series (Elam-Evans et al., 2014; Markowitz et al., 2007; Williams et al., 2014). 
HPV vaccine coverage varies substantially among states, with Utah having some of the 
lowest coverage rates in the U.S. (Elam-Evans et al., 2014). Clearly, the Unites States is 
far from the Healthy People 2020 target of 80% HPV vaccine coverage among eligible 
females, indicating an urgent need for interventions (Elam-Evans et al., 2014).  
Resources are currently available to help increase HPV vaccination in Utah. In 
April 2007, Jon Huntsman, Sr. donated $1 million to the Utah Department of Health to 
educate Utahans about cervical cancer and provide low-cost HPV vaccines to eligible 
women (Collins & Welling, 2007). An additional $25,000 allocated by the Utah 




other healthcare professionals about the HPV vaccine (Collins & Welling, 2007). 
Additionally, the HPV vaccine is available for free or at low cost for girls age 9–18 years 
old through the Vaccines for Children Program and may be available for free or at low 
cost for women age 19–26 years old who have no insurance or insurance that does not 
pay for the vaccine thanks to Vaccine Patient Assistance Programs (CDC, 2014b). The 
results of our study can help to focus these funds and resources to reach women who have 
not yet initiated and/or completed the HPV vaccination series. 
Our study of young women age 18–26 years old found several correlates of 
vaccine initiation and completion that may be useful for future public health interventions 
for this population. Among these correlates were lower age, awareness of HPV 
transmission, knowledge of its connection to cervical cancer, belief in the importance of 
the HPV vaccine, and a physician recommendation (especially a strong 
recommendation). Marital status (being unmarried), practicing organized religion, and 
higher education were also significant predictors of vaccine initiation and completion. 
Cost, being in a monogamous relationship, and novelty of the vaccine were the main 
barriers against vaccination. 
These findings echo previous studies that identified knowledge-attitude-practice 
gaps in the context of the HPV vaccine (Cohen & Head, 2013). The differences we found 
between vaccinated women and unvaccinated women regarding risk beliefs (i.e., the 
vaccine is not personally relevant because they are in a monogamous relationship and the 
vaccine is too new and more information is needed) help explain why increasing uptake 
of the HPV vaccine requires targeted risk communication strategies (Cohen & Head, 




vaccine research: the importance of a consistent and strong recommendation of the HPV 
vaccine from healthcare providers (Darden & Jacobson, 2014; Krawczyk et al., 2012; 
Rosenthal et al., 2011). However, our findings run counter to an earlier study showing no 
association between marital status in their multivariate analysis (Rosenthal et al., 2011). 
This difference could be due to the particular interplay between marriage, age, and 
religiosity in the state of Utah.  
There are limitations to the generalizability of the current study. The majority of 
participants were White/Caucasian (>80%), had access to healthcare, and response rates 
were higher in the vaccinated vs. the unvaccinated, which may have introduced 
unmeasured response bias. Furthermore, cross-sectional study design prohibits 
assessment of causal relationships.  
Conclusions 
The implications of these findings may help inform policies regarding HPV 
vaccination education among young women. For example, without this information, 
programs might focus on awareness (Collins & Welling, 2007; Cui et al., 2010; Gerend 
& Magloire, 2008; Jain et al., 2009), but the results of this study illustrate that the 
significance of awareness of HPV as a predictor of vaccine uptake has diminished over 
time and that programs should now focus on other variables (for example, strong and 
consistent physician recommendations). Additionally, our findings indicate the need for 
discussions of risk assessment tailored to the young adult population since young women 
are sure of their sexual behavior in a way parents may not be of their children’s. These 
interventions may use our results to take into account a patient’s education, religious 




needed to assess the impact these tailored interventions would have on bolstering HPV 
vaccination rates in the low vaccination state of Utah. 
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Table 7. Factor Analysis Results (Utah, January–December 2013) 
Factor  Survey questions 
  
1: Attitudes toward vaccines. 
[Cronbach’s alpha: 0.903 (95% 
CI: (0.880, 0.925))] 
• Vaccines are a good way to protect public health.  
• I do not like the idea of vaccines.a  
• Vaccines are generally safe.  
• Vaccines are a way to take good care of myself now and 
in the future.  
• Vaccines are effective.  
• Vaccines are safe. In particular, HPV vaccine is safe.  
  
2: Regular gynecological care. 
[Cronbach’s alpha: 0.856 (95% 
CI: (0.819, 0.892))] 
• Gynecological/pelvic exams are necessary to stay 
healthy. 
• I get a Pap test/Pap smear according to my 
doctor’s/health care provider’s advice. 
• It is very important to have an annual pelvic exam. 
  
3: Comfort with sexual health 
(care). [Cronbach’s alpha: 0.754 
(95% CI: (0.701, 0.807))] 
• I am comfortable discussing sexual health issues with a 
doctor or nurse. 
• I am comfortable discussing sexual health issues with 
others such as family or friends. 
• I don’t mind getting a gynecological/pelvic exam. 
  
4: External locus of health 
control 1: (medical professionals 
drive health). [Cronbach’s alpha: 
0.720 (95% CI: (0.668, 0.772))] 
• Having regular contact with my physician is the best 
way for me to avoid illness. 
• Whenever I don’t feel well, I should consult a medically 
trained professional.  
• Health professionals control my health.  
• Regarding my health, I can only do what my doctor tells 
me to do.  
  
5: Internal locus of health 
control. [Cronbach’s alpha: 
0.734 (95% CI: (0.680, 0.788))] 
• I am in control of my health.  
• The main thing which affects my health is what I myself 
do.  
• If I take care of myself, I can avoid illness.  
• If I take the right actions, I can stay healthy. 
  
6: External locus of health 
control 2: (health matter of luck). 
[Cronbach’s alpha: 0.646 (95% 
CI: (0.570, 0.722))] 
• Luck plays a big part in determining how soon I will 
recover from an illness. 
• My good health is largely a matter of good fortune. 
• If it’s meant to be, I will stay healthy 
  
7: Comfort with shots. 
[Cronbach’s alpha: 0.729 (95% 
CI: (0.660, 0.797))] 
• I am not afraid of shots. 
• Shots are very painful.a 
 •  




Table 8. Characteristic of Study Participants (Utah, January–December 2013) 
 
No doses  
 (n = 121) n 
(%)  
1+ dose  
 (n = 204)  
n (%)  
3 dose 
completion (n = 
159)  
n (%)  
    
Age  
18 - 21.5 y.o. 28 (23.14) 82 (40.20) 65 (40.88) 
22 - 24 y.o. 48 (39.67) 70 (34.31) 53 (33.33) 
24.5 - 26 y.o. 45 (37.19) 52 (25.49) 41 (25.79) 
    
Race/ethnicity   
Asian 9 (7.44) 8 (3.92) 8 (5.03) 
Black or African American 2 (1.65) 4 (1.96) 3 (1.89) 
Hispanic or Latina 9 (7.44) 15 (7.35) 10 (6.29) 
White/Caucasian 96 (79.34) 167 (81.86) 133 (83.65) 
Other 5 (4.13) 10 (4.90) 5 (3.14) 
    
Highest level of education   
Up to or graduated high school 24 (19.83) 25 (12.25) 17 (10.69) 
Some college, but no degree 39 (32.23) 90 (44.12) 72 (45.28) 
College degree 46 (38.02) 77 (37.75) 60 (37.74) 
Graduate school 12 (9.92) 12 (5.88) 10 (6.29) 
    
Marital status  
Single, never married 66 (54.55) 165 (80.88) 132 (83.02) 
 (Ever) Married 54 (44.63) 38 (18.63) 26 (16.35) 
    
Ever received a cancer diagnosis  
Yes 3 (2.48) 3 (1.47) 2 (1.26) 
No 118 (97.52) 199 (97.55) 155 (97.48) 
    
Know anyone who has had a cancer diagnosis  
Yes 95 (79.51) 178 (87.25) 140 (88.05) 
No 26 (21.49) 26 (12.75) 19 (11.95) 
    
Know anyone who has had cervical cancer  
Yes 9 (9.57) 24 (13.04) 18 (12.59) 
No 85 (90.43) 160 (86.96) 125 (87.41) 
    
Practice organized religion  
Yes 72 (59.50) 75 (36.95) 53 (33.54) 
No 49 (40.50) 128 (63.05) 105 (66.46) 
    
Religion guide your daily decisions  
Yes 57 (65.52) 51 (48.57) 38 (48.10) 
No 30 (34.48) 54 (51.43) 41 (51.90) 




Table 9. Participants’ Attitudes about and Knowledge Relating 
to the HPV Vaccine (Utah, January–December 2013) 
 
No doses 
 (n = 119)  
n (%)  
1+ dose  
 (n = 202)  
n (%)  
3 dose 
completion  
 (n = 157)  
n (%)  
    
Have you ever heard of human 
papillomavirus (HPV)?  
   
Yes 105 (86.78) 200 (98.04) 155 (97.48) 
No 16 (13.22) 4 (1.96) 4 (2.52) 
Do you know how HPV is spread?     
Yes 72 (59.50) 185 (90.69) 144 (90.57) 
No 49 (40.50) 19 (9.31) 15 (9.43) 
Have you ever heard of a relationship 
between HPV and cervical cancer? 
   
Yes 78 (65.00) 180 (88.24) 143 (89.94) 
No 42 (35.00) 24 (11.76) 16 (10.06) 
Have you ever heard of a vaccine to prevent 
HPV (e.g., Gardasil® or Cervarix®)? 
   
Yes 90 (75.00) 203 (100) 158 (100) 
No 30 (25.00) 0 (0) 0 (0) 
 (If heard of vaccine) how important do you 
think the vaccine to help prevent cervical 
cancer is for you? 
   
Not at all important 10 (11.11) 5 (2.45) 2 (1.26) 
Not very important 18 (20.00) 6 (2.94) 0 (0) 
Somewhat important 27 (30.00) 50 (24.51) 33 (20.75) 
Very important 35 (38.89) 143 (70.10) 124 (77.99) 
Have you discussed the vaccine to help 
prevent cervical cancer with a doctor? 
   
Yes 34 (37.36) 201 (98.53) 158 (99.37) 
No 57 (62.64) 3 (1.47) 1 (0.63) 
Did a doctor recommend that you get the 
vaccine to help prevent cervical cancer? 
   
Yes 22 (55.00) 199 (98.03) 157 (99.37) 
No 18 (45.00) 4 (1.97) 1 (0.63) 





Table 10. Crude and Adjusted Odds Ratios (95% CIs) for Predictors of Vaccination 
Initiation and Completion and Adjustment Variables Used in Regression 

















(1.39 - 2.11) 
1.86  
(1.46 - 2.36) 
1.85  
(1.46 - 2.34) 
2.01  
(1.53 - 2.63)  
Factor 1: Attitudes toward 
vaccines, Age 




(0.77 - 0.94) 
0.87  
(0.77 - 1.00) 
0.87  
(0.79 - 0.95) 
0.88  
(0.77 - 0.99) 
Education level, Factor 2: 
Regular Gynecological 
care, Factor 4: External 
locus of health control 1: 
(medical pros), Factor 5: 
Internal locus of health 
control, Marital status 
      
Education  
(ref: High school) 
 Age 
Some college 2.22  
(1.13 - 4.35) 
2.33  
(1.15 - 4.70) 
2.38  
(1.20 - 4.71) 
2.53 
(1.25 -5.14) 
     
College graduate 1.61  
(0.82 - 3.14) 
2.72  
(1.26 - 5.88) 
1.79  
(0.90 - 3.56) 
3.07  
(1.39 - 6.77) 
Graduate school 0.96  
(0.36 - 2.55) 
1.62  
(0.55 - 4.76) 
1.34  
0.49 - 3.66) 
2.26  






(0.67 - 2.07) 
1.10  
(0.60 - 2.00) 
1.42  
(0.81 - 2.49) 
1.30  
(0.72 - 2.34) 
Education level, Age 
Marital status (ever 
vs never married) 
0.28  
(0.17 - 0.47) 
0.31  
(0.18 - 0.53) 
0.30  
(0.18 - 0.50)  
0.32  
(0.18 - 0.56) 
Age, Factor 2: Regular 
Gynecological care, Factor 
4: External locus of health 
control 1: (medical pros), 
Factor 5: Internal locus of 
health control 
      
Practice Organized 
Religion  




(0.25 - 0.67) 
0.38  
(0.25 - 0.61) 
0.40  
(0.25 - 0.64) 
Factor 1: Attitudes toward 
vaccines, Physician 
recommendation 











Figure 15. Potential Confounders of Predictors of HPV Vaccine 















Figure 16. Reasons for Not Initiating or Completing the 














The data from study one indicate that the overall positivity of HPV is declining, 
especially in young women; however, the rate at which positivity is declining is slower 
than other studies indicate in certain age categories (Markowitz et al., 2013). Additionally, 
these rates of decline are slower than expected by mathematical models given adequate 
vaccine coverage (Barnabas et al., 2006). These results indicate a need for improved 
vaccination rates and, subsequently, the need for evidence-driven programs aimed to 
improve these vaccination rates. Furthermore, our initial study demonstrates the potential 
for using HPV test data from large national reference laboratories to supplement the 
ongoing and planned efforts to monitor HPV vaccine impact in the US (Markowitz et al., 
2010). 
To inform these vaccine programs, and the goal of study two, the meta-analysis of 
published research identified potential factors that may influence both intention to 
recommend the HPV vaccine, and intention to receive the vaccinate. One of the more 
compelling findings, and one that further drives the need for future interventions, is that 
individual intention to receive the vaccine is not increasing over time, and may, in fact, 
be decreasing over time. The remainder of study two identifies factors that may be 
pivotal to increase vaccination rates—both in physician intention to vaccinate, and 




One of these potential factors driving physician intention to prescribe the vaccine 
was age of intended recipient. Although the proportion of physicians who intended to 
recommend the HPV vaccination was high (ranging from 66% to 97%), there was a high 
degree of heterogeneity (overall I2 = 96.4%) between studies and much of this 
heterogeneity may be attributable to age of intended recipient. Physicians were more 
likely to recommend vaccination to older girls. The proportion of physicians likely to 
vaccinate were 73% (95% CI: 68%-78%), 89% (95% CI: 76%-95%), and 95% (95% CI: 
84%-98%) for recipients aged less than 14 years, 14–17 years, and greater than 17 years, 
respectively (p=0.0014). This runs counter to the ACIP guidelines, recommending 
routine HPV vaccination of females aged 11 or 12 years or catch-up vaccination in 
women 13–26 years of age (Markowitz et al., 2007). Additionally, as we found physician 
recommendation was a strong predictor of vaccination intention both in parents and 
individuals, a campaign to increase vaccination rates might better focus on increasing 
physician’ early, strong recommendations to follow the appropriate vaccination schedule.  
Finally, study three showed that there are similarities between the Utah population 
and the general U.S. population regarding factors related to vaccine intention, e.g., 
physician recommendation is very influential. However, there are particularities of the 
population of Utah that might require further message tailoring and this study helped to 
inform those future interventions. Particularly, age, marital status, religious practice, and 
education level were significantly associated with vaccine intention.  
The next steps following these studies are to create a community intervention 
targeted both toward receptive individuals, as identified by our studies, and also, and 




Preliminary interventions to increase vaccination rates in Utah could target 
increasing Utah physician's likelihood of recommending the HPV vaccine. Initial steps 
would include assessing baseline physicians' intention to recommend the vaccine and also 
to identify physicians with a very high likelihood of recommending the vaccine, i.e., the 
positive-deviant physician recommenders. This physician group could provide insights 
into scripting that could be used to increase vaccination likelihood in their peer 
physicians. Follow-up would then be performed to evaluate the impact of the intervention 
on increased physician intention to vaccinate and, subsequently, increased HPV 
vaccination rates in Utah. 
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